Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | THRB | P10828 | 1/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.37 |
| ▸ | KDM6B | O15054 | 1/20 | 0.37 |
| ▸ | KDM5C | P41229 | 1/20 | 0.37 |
| ▸ | EGLN1 | Q9GZT9 | 1/20 | 0.37 |
| ▸ | PHF8 | Q9UPP1 | 1/20 | 0.37 |
| ▸ | KDM2A | Q9Y2K7 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.32 |
| ▸ | GPR84 | Q9NQS5 | 4/20 | 0.31 |
| ▸ | MGAM | O43451 | 1/20 | 0.31 |
| ▸ | GAA | P10253 | 1/20 | 0.31 |
| ▸ | SI | P14410 | 1/20 | 0.31 |
| ▸ | MGAM2 | Q2M2H8 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5107560 | 1.00 | THRB (0.39) | THRBKDM4EKDM6BKDM5CEGLN1 | |
| SCHEMBL10740374 | 0.83 | GPR84 (0.39) | KDM4EKDM6BKDM5CEGLN1PHF8 | |
| SCHEMBL20530464 | 0.81 | — | — | |
| SCHEMBL20530462 | 0.81 | — | — | |
| SCHEMBL12722982 | 0.81 | ALDH1A1 (0.41) | KDM4EKDM6BKDM5CEGLN1PHF8 | |
| SCHEMBL27768581 | 0.77 | THRB (0.42) | THRB | |
| SCHEMBL12894212 | 0.77 | KDM4E (0.39) | KDM4EKDM6BKDM5CEGLN1PHF8 | |
| SCHEMBL12384861 | 0.77 | KDM4E (0.39) | KDM4EKDM6BKDM5CEGLN1PHF8 | |
| SCHEMBL18782546 | 0.77 | THRB (0.46) | THRBGPR84 | |
| SCHEMBL16690276 | 0.77 | THRB (0.46) | THRBGPR84 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 47 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11890264-B2 | Migraine prevention and treatment | UNIVERSITATS-KINDERSPITAL BEIDER BASEL (CH) | 2024-02-06 | — | — | US | claimed |
| EP-3558280-B1 | MIGRAINE PREVENTION AND TREATMENT | UNIV KINDERSPITAL BEIDER BASEL (CH) | 2023-06-07 | — | — | EP | claimed |
| US-20210338618-A1 | MIGRAINE PREVENTION AND TREATMENT | UNIVERSITATS-KINDERSPITAL BEIDER BASEL (CH) | 2021-11-04 | — | — | US | claimed |
| EP-2500017-B1 | Use of ketogenic compounds for treatment of age-associated memory impairment | ACCERA INC (US) | 2017-09-06 | — | — | EP | claimed |
| US-20250275986-A1 | COMBINATION OF A KETONE BODY OR KETOGENIC COMPOUND WITH AN ANALGESIC OR ANTIOXIDANT | KETOSWISS AG (CH) | 2025-09-04 | — | — | US | disclosed |
| CN-117677383-A | Combinations of ketone bodies or ketone-forming compounds, analgesics or antioxidants | 瑞士凯托股份公司 | 2024-03-08 | — | — | CN | disclosed |
| EP-4245368-A2 | MIGRAINE PREVENTION AND TREATMENT | Universitäts-kinderspital Beider Basel (CH) | 2023-09-20 | — | — | EP | disclosed |
| EP-3558280-B1 | MIGRAINE PREVENTION AND TREATMENT | UNIV KINDERSPITAL BEIDER BASEL (CH) | 2023-06-07 | — | — | EP | disclosed |
| US-10568854-B2 | Compositions and methods for treating kabuki syndrome and related disorders | THE JOHNS HOPKINS UNIVERSITY (US) | 2020-02-25 | — | — | US | disclosed |
| US-20180098956-A1 | THERAPEUTIC COMPOSITIONS | BTG INT LTD (GB) | 2018-04-12 | — | — | US | disclosed |
| EP-2500017-B1 | Use of ketogenic compounds for treatment of age-associated memory impairment | ACCERA INC (US) | 2017-09-06 | — | — | EP | disclosed |
| US-20170100354-A1 | COMPOSITIONS AND METHODS FOR TREATING KABUKI SYNDROME AND RELATED DISORDERS | THE JOHNS HOPKINS UNIVERSITY (US) | 2017-04-13 | — | — | US | disclosed |
| EP-1123094-A1 | THERAPEUTIC COMPOSITIONS (II) | BTG INTERNATIONAL LIMITED (GB) | 2001-08-16 | — | — | EP | disclosed |
| US-6207856-B1 | INSULIN RESISTANCE, CARDIAC EFFICIENCY, TREATING DISORDERS CAUSED BY DAMAGE TO BRAIN CELLS IN MEMORY, KETONE BODIES, POLYESTERS OF 3-HYDROXYBUTYRIC ACID | BTG INTERNATIONAL LIMITED (GB) | 2001-03-27 | — | — | US | disclosed |
| EP-1017379-A1 | THERAPEUTIC COMPOSITIONS | BTG INTERNATIONAL LIMITED (GB) | 2000-07-12 | — | — | EP | disclosed |
| CN-1256629-A | Therapeutic compositions | BRITISH TECH GROUP (GB) | 2000-06-14 | — | — | CN | disclosed |
| WO-2000015216-A1 | THERAPEUTIC COMPOSITIONS (II) | BTG INTERNATIONAL LIMITED (GB) | 2000-03-23 | — | — | WO | disclosed |
| WO-1998041201-A9 | THERAPEUTIC COMPOSITIONS | — | 1999-03-11 | — | — | WO | disclosed |
| WO-1998041201-A1 | THERAPEUTIC COMPOSITIONS | BTG INTERNATIONAL LIMITED (GB) | 1998-09-24 | — | — | WO | disclosed |
| WO-1998041200-A1 | THERAPEUTIC COMPOSITIONS | BTG INTERNATIONAL LIMITED (GB) | 1998-09-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180098956-A1 | THERAPEUTIC COMPOSITIONS | CPT1B, IAPP, GYS1 | THRB 1830/4885KDM4E 3383/4885KDM6B 3475/4885 |
| US-20210338618-A1 | MIGRAINE PREVENTION AND TREATMENT | ACACA, ACACB, HBB | THRB 907/4885KDM4E 2872/4885KDM6B 2206/4885 |
| US-11890264-B2 | Migraine prevention and treatment | ACACA, ACACB, HBB | THRB 907/4885KDM4E 2872/4885KDM6B 2206/4885 |
| US-20250275986-A1 | COMBINATION OF A KETONE BODY OR KETOGENIC COMPOUND WITH AN ANALGESIC OR ANTIOXIDANT | PKM, KCNMA1, KCNK18 | THRB 3525/4885KDM4E 1040/4885KDM6B 2320/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.